AtriCure (ATRC) Expected to Release Earnings on Tuesday

AtriCure (NASDAQ:ATRC) will likely be releasing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect AtriCure to post earnings of ($0.0485) per share and revenue of $151.05 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

AtriCure Price Performance

Shares of ATRC opened at $61.25 on Monday. The business’s 50-day moving average is $55.58 and its two-hundred day moving average is $38.16. The company has a market capitalization of $3.12 billion, a P/E ratio of 291.68 and a beta of 1.22. AtriCure has a fifty-two week low of $25.36 and a fifty-two week high of $63.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ATRC. BTIG Research raised their target price on AtriCure from $55.00 to $63.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Wednesday, October 21st. UBS Group lowered AtriCure from a “buy” rating to a “sell” rating in a research report on Wednesday, October 21st. Needham & Company LLC raised their price objective on shares of AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. Finally, Stifel Nicolaus set a $65.00 target price on shares of AtriCure in a report on Thursday, September 17th. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $55.70.

Insider Activity at AtriCure

In other AtriCure news, Director Karen Prange sold 3,564 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the sale, the director directly owned 22,809 shares of the company’s stock, valued at approximately $884,989.20. This trade represents a 13.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Regina Groves sold 5,313 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $54.22, for a total value of $288,070.86. Following the transaction, the director directly owned 34,546 shares of the company’s stock, valued at approximately $1,873,084.12. The trade was a 13.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 37,686 shares of company stock valued at $1,898,756 in the last ninety days. 4.00% of the stock is currently owned by company insiders.

About AtriCure

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.